JP4509517B2 - Agent that inhibits Staphylococcus aureus skin adhesion and promotes Staphylococcus epidermidis skin adhesion - Google Patents

Description

  The present invention relates to a skin adhesion inhibitor for Staphylococcus aureus.

From skin lesions of atopic dermatitis patients, since Staphylococcus aureus is a pathogen high rate and high concentration is detected, strong involvement in atopic dermatitis Staphylococcus aureus (Staphylococcus aureus) long Has been suggested. Today, atopic dermatitis is also one of the social problems, so studies to clarify the significance of Staphylococcus aureus in the skin lesions have been conducted energetically, but there are still many unclear points. . However, the fact that Staphylococcus aureus is detected at a high rate and high concentration from the skin lesions in atopic dermatitis indicates that Staphylococcus aureus is deeply involved in the pathogenesis and exacerbation of atopic dermatitis. It is shown. Therefore, various countermeasures against Staphylococcus aureus have been proposed for the purpose of improving the condition of the skin surface of patients with atopic dermatitis.

Under the above circumstances, the effectiveness of the atopic dermatitis glucooligosaccharide (in the present invention means a maltose-sucrose condensation product) is expected. Gluco-oligosaccharides are known as substances that can be preferentially assimilated by microorganisms that are harmless to the human body, such as Staphylococcus epidermidis . Therefore, if this property of gluco-oligosaccharide is applied to atopic dermatitis, gluco-oligosaccharide functions as a skin resident bacteria control agent. By preferentially growing microorganisms that are harmless to the human body, such as Staphylococcus epidermidis, yellow It is expected that the growth of pathogenic bacteria such as staphylococci can be suppressed, and as a result, the condition of the skin surface can be improved. Utilizing such a concept, for example, Patent Document 1 and Patent Document 2 describe skin cosmetics and skin external preparations having an improvement effect on atopic dermatitis in which glucooligosaccharide and ceramide or sugar ceramide are mixed. Has been. However, as described in these patent documents, the combination of glucooligosaccharides alone does not sufficiently improve the symptoms of atopic dermatitis. The function is not always satisfactory. This indicates that, in atopic dermatitis, S. aureus adhering to the skin surface is once proliferated, and thus there is a limit to suppressing the proliferation. A method for removing Staphylococcus aureus adhering to the skin surface by washing or the like has also been proposed, but its effect lasts only for a short time and is insufficient. Therefore, it is useful to pay attention to how Staphylococcus aureus does not adhere to the skin surface as a countermeasure against Staphylococcus aureus for the purpose of improving the condition of the skin surface of patients with atopic dermatitis. .

  Then, an object of this invention is to provide the skin adhesion inhibitor of S. aureus.

  As a result of various investigations in view of the above points, the present inventors have found that staphylococcus aureus adheres to the skin surface in addition to the above-mentioned action as a skin resident bacteria control agent. It has been found that there is an action to inhibit.

The present invention has been made on the basis of the above findings , and the agent that inhibits the skin adhesion of Staphylococcus aureus and promotes the skin adhesion of Staphylococcus epidermidis according to the present invention is, as described in claim 1, maltose -It is characterized by using sucrose condensate as an active ingredient.
The skin external preparation or skin cosmetic for inhibiting skin adhesion of Staphylococcus aureus and promoting skin adhesion of Staphylococcus epidermidis according to the present invention is a maltose-sucrose condensate according to claim 2. As an active ingredient.
Further, the external preparation for skin or skin cosmetic composition of the present invention, as claimed in claim 3, wherein the maltose-sucrose condensation, inhibit the skin adhesion of Staphylococcus aureus, and to promote skin adhesion of S. epidermidis It contains as an agent, It is characterized by the above-mentioned.
The skin external preparation or skin cosmetic according to claim 4 is the skin external preparation or skin cosmetic according to claim 2 or 3, further comprising an anti-inflammatory agent, a vitamin agent, a moisturizing agent, an antibacterial agent and a local anesthetic agent. It comprises at least one medicinal component selected from the group consisting of:

  According to the present invention, a staphylococcus aureus skin adhesion inhibitor is provided.

  The staphylococcus aureus skin adhesion inhibitor of the present invention is characterized by comprising glucooligosaccharide as an active ingredient. The staphylococcus aureus skin adhesion inhibitor of the present invention has a problem that, for example, Staphylococcus aureus adheres to the skin surface and proliferates through plasma components exuded from scratches such as atopic dermatitis. Useful for prevention of diseases that develop and worsen. It is also useful for trauma such as scratches, scratches and cuts in which plasma components exude outside the body.

  As the glucooligosaccharide which is an active ingredient of the skin adhesion inhibitor of S. aureus of the present invention, for example, (O-α-D-glucopyranosyl-) obtained from a natural sugar maltose and sucrose by an immobilized enzyme method is used. (1 → 2))-(O-α-D-glucopyranosyl- (1 → 6))-(O-α-D-glucopyranosyl- (1 → 4))-(O-α-D-glucopyranose) The thing which has a structure is mentioned. Such a gluco-oligosaccharide is commercially available, for example, as BIOECOLIA (registered trademark: Soravia).

  The staphylococcus aureus skin adhesion inhibitor of the present invention is an ointment, gel, liquid, lotion or the like as a skin external preparation for inhibiting staphylococcus aureus skin adhesion, body washing, hand washing It can be put to practical use as a skin cosmetic for inhibiting the adhesion of Staphylococcus aureus to the skin in the form of detergents such as cosmetics and facial cleansers, lotions, emulsions, creams and packs. That is, according to the present invention, glucooligosaccharide can be used as a skin staphylococcus aureus skin adhesion inhibitor in an external preparation for skin or skin cosmetics for practical use. The application method may be in accordance with a general application method such as a skin external preparation or skin cosmetic, and can be used by applying an appropriate amount to the outer skin such as skin once to several times a day.

  The staphylococcus aureus skin adhesion inhibitor of the present invention can be prepared in any known dosage form by a conventional method. For example, when it is formulated as a skin external preparation or skin cosmetic, a commonly used base is used. And additives can be appropriately selected and blended to prepare a dosage form such as cream, emulsion, lotion, gel, etc. by a conventional method. In addition to gluco-oligosaccharides, pigments, fragrances, preservatives, surfactants, plant extracts, pH adjusters, sequestering agents, oils, gelling agents, polyhydric alcohols, higher alcohols, hydrocarbons, penetration enhancers, pigments, You may mix | blend an antioxidant etc. suitably. The pH of the preparation when the S. aureus skin adhesion inhibitor of the present invention is formulated into a skin external preparation or skin cosmetic may be any pH that does not cause skin irritation, and is pH 4.0 to 8.0. Particularly preferred is pH 4.0 to 6.0.

  When formulating as a skin external preparation or skin cosmetic, the content of the gluco-oligosaccharide in the preparation is not limited as long as the effect of the present invention is exerted, but usually 0.001 to 30% by weight based on the total amount of the preparation, Preferably it is 0.01 to 20 weight%, More preferably, it is 0.01 to 10 weight%, Most preferably, it is 0.01 to 5 weight%.

  By adding other medicinal ingredients to the external preparation for skin and skin cosmetics, the effects of the present invention can be enhanced or further effects can be imparted. Such a medicinal component is not particularly limited as long as it has a medicinal effect on the skin and mucous membranes, and is a component that provides all desirable effects such as healing and improvement of inflammation and damage occurring on the skin and mucous membranes, and skin protection. Say. Specific examples of such medicinal components include anti-inflammatory agents, vitamin agents, moisturizers, antibacterial agents, and local anesthetics.

  Anti-inflammatory agents include, for example, glycyrrhizic acid and glycyrrhizic acid derivatives such as dipotassium glycyrrhizinate and monoammonium glycyrrhizinate, glycyrrhetinic acid or derivatives thereof, allantoin or derivatives thereof, ε-aminocaproic acid, licorice extract, menthol, camphor, etc. Can be illustrated. Preferred are licorice extract, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, glycyrrhetinic acid, allantoin, ε-aminocaproic acid, menthol and camphor.

  These components can be used alone or in combination of two or more. The compounding amount of these anti-inflammatory agents is not particularly limited, but is usually 0.01 to 5% by weight, preferably 0.01 to 3% by weight, more preferably 0.01 to 2% by weight, depending on the purpose. Can be appropriately selected and adjusted.

  Examples of vitamin agents include retinol derivatives such as retinol, retinol acetate, and retinol palmitate (vitamins A), retinal, retinoic acid, methyl retinoic acid, ethyl retinoic acid, retinol retinoic acid, vitamin A oil, vitamin A fatty acid ester Such as vitamin A, β-carotene, α-carotene, γ-carotene, δ-carotene, lycopene, zeaxanthin, cryptoxanthine, echinone and other provitamins A, dl-α-tocopherol, dl-α-tocopherol acetate, Vitamin E such as dl-α-tocopherol succinate, dl-α-tocopherol calcium succinate, riboflavin, flavin mononucleotide, flavin adenine dinucleotide, riboflavin butyrate ester, riboflavin tetrabutyrate ester Vitamin B2 such as sodium riboflavin 5'-phosphate ester, riboflavin tetranicotinate ester, dl-α-tocopherol nicotinate, benzyl nicotinate, methyl nicotinate, β-butoxyethyl nicotinate, 1- (nicotinate Nicotinic acids such as 4-methylphenyl) ethyl, vitamin C such as ascorbic acid-A, ascorbic acid stearate, ascorbyl palmitate, L-ascorbyl dipalmitate, methyl hesperidin, ergocalciferol, cholecalciferol, etc. Vitamin D of the above, vitamin Ks such as phylloquinone and farnoquinone, and γ-oryzanol. Dibenzoyl thiamine, dibenzoyl thiamine hydrochloride, thiamine hydrochloride, thiamine cetyl hydrochloride, thiamine thiocyanate, thiamine lauryl hydrochloride, thiamine nitrate, thiamine monophosphate, thiamine lysine salt, thiamine triphosphate, thiamine monophosphate Vitamin B1 such as acid ester phosphate, thiamine monophosphate, thiamine diphosphate, thiamine diphosphate hydrochloride, thiamine triphosphate, thiamine triphosphate monophosphate, pyridoxine hydrochloride, pyridoxine acetate, pyridoxal hydrochloride, Vitamin B6 such as pyridoxal 5'-phosphate and pyridoxamine hydrochloride, vitamin B12 such as cyanocobalamin, hydroxocobalamin, deoxyadenosylcobalamin, folic acid, pteroylglutamine Folic acid, nicotinic acid such as nicotinic acid, nicotinic acid amide, pantothenic acid, calcium pantothenate, pantothenyl alcohol (panthenol), D-panthecin, D-panthetin, coenzyme A, pantothenyl ethyl ether, etc. Pantothenic acids, biotins such as biotin and biotin, ascorbic acid, sodium ascorbate, dehydroascorbic acid, sodium ascorbate phosphate, vitamin C which is an ascorbic acid derivative such as magnesium ascorbate phosphate, in addition to carnitine, Examples thereof include vitamin-like agents such as ferulic acid, α-lipoic acid and orotic acid.

Preferably, retinol, retinol acetate, retinol palmitate, retinal, retinoic acid, ascorbic acid, sodium ascorbate, sodium ascorbate phosphate, magnesium ascorbate phosphate, magnesium ascorbate stearate, ascorbyl palmitate, Riboflavin, riboflavin butyrate, riboflavin sodium 5'-phosphate, pantothenic acid, calcium pantothenate, retinol, vitamin A oil, vitamin A fatty acid ester, methyl hesperidin, folic acid, dibenzoylthiamine, dibenzoylthiamine hydrochloride, thiamine hydrochloride Salt, thiamine cetyl hydrochloride, thiamine thiocyanate, thiamine lauryl hydrochloride, nicotinic acid, nicotinamide, β-carotene, Goka Cie Fellows Le, cholecalciferol, pyridoxine hydrochloride, a panthenol, dl-alpha-tocopherol and acetic acid dl-alpha-tocopherol.
More preferably, retinol, retinol acetate, retinol palmitate, retinal, retinoic acid, ascorbic acid, magnesium ascorbate phosphate, stearic acid ascorbate, nicotinic acid, nicotinamide, β-carotene, ergocalciferol, cholecalci Ferrol and pyridoxine hydrochloride.

  These components can be used alone or in combination of two or more. The blending amount of these vitamins is not particularly limited, but is usually 0.01 to 10% by weight, preferably 0.01 to 5% by weight, more preferably 0.01 to 2% by weight, depending on the purpose. It can be appropriately selected and adjusted.

  Examples of the humectant include polyethylene glycol, propylene glycol, glycerin, sorbitol, mannitol, glucose, sucrose, fructose, xylitol, lactose, maltose, maltitol and other polyhydric alcohols, sodium hyaluronate, heparin analog, chondroitin sulfate Biomolecules such as sodium, collagen, elastin and keratin, amino acids such as glycine, aspartic acid and arginine, natural moisturizing factors such as sodium lactate, urea and sodium pyrrolidonecarboxylate, and lipids such as ceramide, cholesterol and phospholipid Etc. In addition, plant extracts such as lavender extract, eucalyptus extract and peppermint extract can be exemplified. Preferably, glycerin, sodium hyaluronate, heparin analogue, sodium chondroitin sulfate, collagen, keratin, glycine, aspartic acid, arginine, sodium lactate, urea, sodium pyrrolidone carboxylate, ceramide, cholesterol, lavender extract, eucalyptus extract, peppermint extract It is.

  These components can be used alone or in combination of two or more. The amount of the moisturizing agent is not particularly limited, but is usually appropriately selected and adjusted from the range of 0.005 to 20% by weight, preferably 0.01 to 10% by weight, more preferably 0.01 to 5% by weight. be able to.

Examples of the antibacterial agent include isopropylmethylphenol, chlorhexidine hydrochloride, benzalkonium chloride, cetylpyridinium chloride and the like.
These components can be used alone or in combination of two or more. The blending amount of these antibacterial agents is not particularly limited, but is usually appropriately selected and adjusted from the range of 0.001 to 10% by weight, preferably 0.001 to 5% by weight, more preferably 0.001 to 1% by weight. Can do.

Examples of the local anesthetic include eucalyptus oil, eugenol, menthol, camphor, mint oil and the like.
These components can be used alone or in combination of two or more. The blending amount of these local anesthetics is not particularly limited, but can be appropriately selected and adjusted from the range of usually 0.01 to 20% by weight, preferably 0.1 to 15% by weight.

  The S. aureus skin adhesion inhibitor of the present invention effectively inhibits S. aureus from adhering to the skin surface, whether applied before or after the plasma component exudes outside the body. It is useful for the prevention of diseases in which disorders occur or worsen due to the growth of Staphylococcus aureus adhering to the skin surface through plasma components that have exuded from the wound, and a therapeutic agent for atopic dermatitis, wound healing agent It is preferable to use as such.

  The present invention will be described in more detail with reference to the following test examples and examples, but the present invention should not be construed as being limited in any way based on the following description. In the following test examples and examples, BIOECOLIA (registered trademark: Soravia) was used as the glucooligosaccharide.

The following Test Example 1 and Test Example 2 were performed using two strains (coagulase II type AD1 and coagulase type VII AD2) collected from the skin lesions of atopic dermatitis patients as S. aureus strains. The minimum inhibitory concentration (MIC) of oxacillin for both strains was 128 μg / ml for AD1 and 0.12 μg / ml for AD2. These Staphylococcus aureus were obtained by growing overnight at 37 ° C. without shaking in 8 ml TSB medium (Nissui Pharmaceutical Co., Ltd.), and then centrifuging at 6000 g for 10 minutes at 4 ° C. Then, resuspend in sterile saline and centrifuge under the same conditions as above. Repeat this operation a total of 3 times, then resuspend in a 1 ml polypropylene microcentrifuge tube or tissue culture dish (35 x 10 mm). The solution became cloudy and was inoculated as a suspension. Inoculation with S. aureus was performed in the range of 8.4 × 10 ^{7 to} 2.1 × 10 ⁷ cfu / ml. In addition, the statistical treatment in the following Test Example 1 and Test Example 2 was based on a t-test for comparison of two unmatched groups.

Test Example 1: Observation of growth of Staphylococcus aureus in various media (method)
Two types of S. aureus (AD1 and AD2) suspensions were separately inoculated into 1 ml of the test solution described in Table 1. After incubation at 37 ° C. for 24 hours, the number of bacteria in each test solution was counted by a 10-fold dilution method.
(result)
Table 1 shows. As is apparent from Table 1, the number of Staphylococcus aureus in 0.5% saline containing 5% glucooligosaccharide is 1/10 or less of the number of Staphylococcus aureus in 0.5% saline as a control. Yes, the number of bacteria was small (P <0.01). The pH of 5% glucooligosaccharide-added 0.5% saline was 4.8, which was lower than the control pH of 0.5% saline 6.6. That is, the pH was reduced by adding 5% glucooligosaccharide. On the other hand, the number of Staphylococcus aureus bacteria in PBS supplemented with 5% glucooligosaccharide was not reduced compared to the number of Staphylococcus aureus bacteria in PBS as a control. The pH of PBS containing 5% glucooligosaccharide and the pH of PBS (phosphate buffered saline) as a control was 7.4, and no decrease in pH was observed due to the addition of 5% glucooligosaccharide. Moreover, although data are not shown, even if 5% gluco-oligosaccharide is added to 0.5% tryptone-added 0.5% saline, the pH does not decrease and the number of Staphylococcus aureus bacteria does not decrease. From the above results, it was suggested that 5% glucooligosaccharide suppresses the growth of Staphylococcus aureus in a slightly acidic pH state.

Test Example 2: Observation of adhesion of Staphylococcus aureus on cover glass (method)
A group of cover glass (1.77 cm ² , made of Teflon resin: Sumitomo Bakelite Co., Ltd.) was added to PBS, 5% glucose added PBS, 1% glucooligosaccharide added PBS, 5% glucooligosaccharide added PBS in a tissue culture dish. It was immersed and pretreated at 37 ° C. for 1 hour. The treated cover glass was washed 5 times with 3 ml of PBS. Then, the tissue culture dish was immersed in rabbit plasma (Denka Seken), treated at 37 ° C. for 1 hour, washed 5 times with PBS, and used for the test. Two S. aureus (AD1 and AD2) suspensions were separately inoculated into 3 ml of PBS soaked with these coverslips. After incubating at 37 ° C. for 24 hours, the cover glass is taken out of the solution, gently washed 5 times with 3 ml of PBS, and at 60% power with Ultrasonics model W-225R in 4 ml of PBS at 4 ° C. Was sonicated for 45 seconds, the number of Staphylococcus aureus detached from the cover glass was counted, and the number of Staphylococcus aureus adhering to the cover glass was determined. For reference, the same test was performed using two types of Staphylococcus epidermidis (AD3 and AD4) suspensions prepared in the same manner as the S. aureus suspension.
(result)
It shows in Table 2. As is apparent from Table 2, on the cover glass that had been pretreated with PBS containing 1% glucooligosaccharide and treated with rabbit plasma, and on the cover glass that had been pretreated with PBS containing 5% glucooligosaccharide and treated with rabbit plasma. The number of Staphylococcus aureus adhering was 1/10 or less of the number of Staphylococcus aureus adhering on the cover glass that had been pretreated with PBS as a control and treated with rabbit plasma. The number was small (P <0.01). The number of Staphylococcus epidermidis adhering to the cover glass that had been pretreated with PBS supplemented with 5% glucooligosaccharide and treated with rabbit plasma is the same as the cover glass that had been pretreated with PBS as a control and treated with rabbit plasma. There was no decrease compared to the number of Staphylococcus epidermidis adhering to the top. From the above results, it was found that the treatment with PBS supplemented with 5% glucooligosaccharide inhibited the adhesion of Staphylococcus aureus on the cover glass. However, treatment with PBS supplemented with 5% glucooligosaccharide did not show such an effect on Staphylococcus epidermidis.

Test Example 3: Evaluation test using hairless mice (Method 1)
The skin on the back part of the hairless mouse was peeled off, degreased with an acetone: ether (1: 1) solution, and then immersed in PBS for 2 hours. Thereafter, the skin is cut into a size of about 2 cm ² to prepare two pieces of skin, which are put in two wells of a 24-well plate, and 1 ml of PBS containing 5% glucooligosaccharide as a test solution is added thereto, After incubation at 37 ° C. for 1 hour, the plate was washed 5 times with PBS. Next, 1 ml of rabbit plasma was added to the well, incubated at 37 ° C. for 1 hour, and then washed 5 times with PBS. One well was inoculated with 1 ml of a 1.0 × 10 ⁷ cfu / ml PBS suspension with S. aureus (ATCC 6538 strain) and the other well with S. epidermidis (ATCC 12228 strain) at 37 ° C. And incubated for 24 hours. Thereafter, observation with a scanning electron microscope was performed, the number of adherent bacteria per 100 μm × 80 μm visual field was measured, and the average value was calculated from the measurement results of 10 visual fields. Further, a test similar to the above was performed using PBS as a control instead of PBS containing 5% glucooligosaccharide as a test solution, and an average value was calculated from the measurement results of 10 visual fields. The statistical treatment was based on a t-test for comparison between two unmatched groups.
(Method 2)
The skin on the back part of the hairless mouse was peeled off, degreased with an acetone: ether (1: 1) solution, and then immersed in PBS for 2 hours. Thereafter, the skin was cut to a size of about 2 cm ² to prepare two pieces of skin, put into two wells of a 24-well plate, 1 ml of rabbit plasma was added thereto, and incubated at 37 ° C. for 1 hour. Washed 5 times with PBS. Next, 1 ml of PBS containing 5% glucooligosaccharide as a test solution was added to the wells, incubated at 37 ° C. for 1 hour, and then washed 5 times with PBS. One well was inoculated with 1 ml of a 1.0 × 10 ⁷ cfu / ml PBS suspension with S. aureus (ATCC 6538 strain) and the other well with S. epidermidis (ATCC 12228 strain) at 37 ° C. And incubated for 24 hours. Thereafter, observation with a scanning electron microscope was performed, the number of adherent bacteria per 100 μm × 80 μm visual field was measured, and the average value was calculated from the measurement results of 10 visual fields. Further, a test similar to the above was performed using PBS as a control instead of PBS containing 5% glucooligosaccharide as a test solution, and an average value was calculated from the measurement results of 10 visual fields. The statistical treatment was based on a t-test for comparison between two unmatched groups.
(result)
It is shown in FIG. 1 and FIG. As can be seen from FIG. 1, PBS containing 5% glucooligosaccharide inhibited the adhesion of Staphylococcus aureus to the skin surface, either before or after adding rabbit plasma. However, as is apparent from FIG. 2, the adhesion of Staphylococcus epidermidis to the skin surface was not inhibited but promoted.

Example 1: External preparation for skin (gel agent)
According to a known method, a skin external preparation with a pH of 5.5 having the following composition was produced (unit: w / v).
Gluco-oligosaccharide 5.0%
Carboxyvinyl polymer 0.3%
Triethanolamine 0.1%
Paraben 0.05%
pH adjuster
Purified water
Total 100%

Example 2: Skin cosmetic (lotion)
In accordance with a known method, a skin cosmetic material having the following composition and having a pH of 4.5 was produced (unit: w / v).
Gluco-oligosaccharide 0.001%
Xanthan gum 0.1%
Sodium alginate 0.1%
Phenoxyethanol 0.5%
pH adjuster
Purified water
Total 100%

Example 3: Skin cosmetic (lotion)
In accordance with a known method, a skin cosmetic material having the following composition and having a pH of 5.5 was produced (unit: w / w%).
1,3-butylene glycol 12.0%
Glycerol 3.0%
Gluco-oligosaccharide 2.0%
Collagen tripeptide 0.01%
Allantoin 0.1%
Polyquaternium-51 0.5%
Sodium hyaluronate 0.01%
PEG-1500 0.5%
pH adjuster
Preservative Trace amount
Purified water
Total 100%

Example 4: External preparation for skin (milky lotion)
According to a known method, an external preparation for skin having a pH of 5.0 having the following composition was produced (unit: w / w%).
1,3-butylene glycol 12.0%
Jojoba oil 6.0%
Glycerin 4.0%
Vaseline 3.5%
Polyoxyethylene (40) hydrogenated castor oil 1.5%
Glyceryl stearate 1.2%
Collagen tripeptide 0.1%
Allantoin 0.1%
Carboxyvinyl polymer 0.1%
Xanthan gum 0.1%
Cetanol 0.6%
Panthenol 1.0%
Triethanolamine appropriate amount
Purified water
Total 100%

Example 5: External preparation for skin (cream)
According to a known method, an external preparation for skin having a pH of 5.0 having the following composition was produced (unit: w / w%).
1,3-butylene glycol 15.0%
Vaseline 15.0%
Glycerol 7.0%
Gluco-oligosaccharide 5.0%
Stearyl alcohol 1.0%
Polyoxyethylene (40) hydrogenated castor oil 1.8%
Glyceryl stearate 1.0%
Collagen tripeptide 0.5%
Dipotassium glycyrrhizinate 0.1%
Carboxyvinyl polymer 0.4%
Triethanolamine appropriate amount
Purified water
Total 100%

Example 6: External preparation for skin (gel agent)
According to a known method, a pH 6.0 external preparation for skin having the following composition was produced (unit: w / w%).
Gluco-oligosaccharide 0.5%
Alkyl-modified carboxyvinyl polymer 0.5%
1,3-butylene glycol 5.0%
Phenylmethylpolysiloxane 1.0%
Lavender oil 0.1%
Sodium hyaluronate 0.1%
Menthol 0.1%
Arginine appropriate amount
Purified water
Total 100%

Example 7: Skin cosmetic (cleaning agent)
In accordance with a known method, a skin cosmetic material having the following composition and having a pH of 6.0 was produced (unit: w / w%).
Gluco-oligosaccharide 4.0%
Disodium lauryl polyoxyethylene sulfosuccinate
5.0%
1,2-pentanediol 2.0%
n-Lauroyl-N'-carboxymethyl-N'-hydroxyethylethylenediamine sodium
3.5%
Collagen tripeptide 0.3%
Polyglyceryl laurate 2.0%
Polyoxypropylene (1) Palm oil fatty acid monoisopropanolamide
0.5%
Phenoxyethanol 0.3%
Tea tree oil 0.1%
pH adjuster
Purified water
Total 100%

  The present invention has industrial applicability in that it can provide a staphylococcus aureus skin adhesion inhibitor.

The graph which shows the influence with respect to the adhesion to the skin surface of the Staphylococcus aureus of 5% gluco-oligosaccharide addition PBS in the test example 3. FIG. The graph which shows the influence with respect to adhesion to the skin surface of S. epidermidis same as the above.

Claims (4)

An agent that inhibits the adhesion of Staphylococcus aureus to the skin and promotes the adhesion of Staphylococcus epidermidis, comprising maltose / sucrose condensate as an active ingredient. A skin external preparation or skin cosmetic for inhibiting skin adhesion of Staphylococcus aureus and promoting skin adhesion of Staphylococcus epidermidis, comprising maltose-sucrose condensate as an active ingredient. Maltose Sucrose condensate, inhibit the skin adhesion of Staphylococcus aureus, and skin external agent or skin cosmetic which is characterized by containing as an agent to promote skin adhesion of S. epidermidis.   The skin external preparation according to claim 2 or 3, further comprising at least one medicinal component selected from the group consisting of an anti-inflammatory agent, a vitamin agent, a moisturizer, an antibacterial agent and a local anesthetic. Agent or skin cosmetic.

Images